TARDBP and amyotrophic lateral sclerosis: Research has found that proteasome inhibition, which leads to the accumulation of ubiquitinated TDP‐43 at lysine 95 within its NLS, reduces poly‐GA‐dependent mislocalization of TDP‐43, offering significant therapeutic potential in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia108 (Figure 3D).